Lu et al. [33] confirmed Shikonin's activation of RIP1 and RIP3 in glioma cells, both in vitro and in vivo, through the elevation of intracellular H2O2 and associated glycolysis inhibition. This evidence concerns the gene RIPK3 and central nervous system cancer.